VANCOUVER, British Columbia and SAN DIEGO, Dec. 27, 2018 /PRNewswire/ -- Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today that Dr. Sandra Dunn, PhoenixMD's Chief Executive...
Notes are encrypted so only you can see them.
Environment fund helps support community groups
ASAP Catalytic Ozonation of Ketoprofen with In Situ N-Doped Carbon: A Novel
Electrolytes What Do You Need To Know?
ASAP Water Flow Variability Affects Adsorption and Oxidation of
ASAP Deriving Emission Factors and Estimating Direct Nitrous Oxide
ASAP Formation and Evolution of Solvent-Extracted and Nonextractable